Back to News
Market Impact: 0.2
Ion Beam Enters Distribution Agreement For ARTMS' QIS Technology
Source: Nasdaq
Healthcare & BiotechTechnology & InnovationProduct Launches
Ion Beam Applications signed an agreement with ARTMS, a Telix Pharmaceuticals subsidiary, to distribute its Quantum Irradiation System (QIS) in support of theranostics. The partnership expands potential commercialization and adoption of IBA's medical-technology platform, though no financial terms or revenue impact were disclosed.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.30
Ticker Sentiment
IBAB0.55
TLX0.45
More News
- Nvidia Faces Questions Over China AI Chip Smuggling Cases
- Broadcom to lend Anthropic up to $42 billion to lease its chips, filing says
- $8.2B acquisition validates AI-picked chip stock: +20% since June
- Markets slip on dollar pressure, but this IT stock is up 10% today
- One of our most recent defensive buys cleared a hurdle and its stock jumped
- AI’s biggest players promise to police themselves at the White House